CA2312913A1 - Compounds and methods for the inhibition of protein-protein interactions - Google Patents
Compounds and methods for the inhibition of protein-protein interactions Download PDFInfo
- Publication number
- CA2312913A1 CA2312913A1 CA002312913A CA2312913A CA2312913A1 CA 2312913 A1 CA2312913 A1 CA 2312913A1 CA 002312913 A CA002312913 A CA 002312913A CA 2312913 A CA2312913 A CA 2312913A CA 2312913 A1 CA2312913 A1 CA 2312913A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- group
- amino acid
- target protein
- side chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 263
- 238000000034 method Methods 0.000 title claims abstract description 72
- 230000005764 inhibitory process Effects 0.000 title claims description 27
- 230000004850 protein–protein interaction Effects 0.000 title claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 293
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 293
- 150000001413 amino acids Chemical class 0.000 claims abstract description 133
- 238000006243 chemical reaction Methods 0.000 claims abstract description 92
- 230000004962 physiological condition Effects 0.000 claims abstract description 58
- 230000027455 binding Effects 0.000 claims abstract description 44
- 102000004190 Enzymes Human genes 0.000 claims abstract description 34
- 108090000790 Enzymes Proteins 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 18
- 230000009257 reactivity Effects 0.000 claims description 71
- 125000005647 linker group Chemical group 0.000 claims description 67
- 230000003993 interaction Effects 0.000 claims description 38
- 230000004048 modification Effects 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 19
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000000903 blocking effect Effects 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 60
- 230000000694 effects Effects 0.000 description 38
- 230000001588 bifunctional effect Effects 0.000 description 28
- 238000005457 optimization Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 17
- 230000002457 bidirectional effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229930182555 Penicillin Natural products 0.000 description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 11
- 229940049954 penicillin Drugs 0.000 description 11
- 102000003777 Interleukin-1 beta Human genes 0.000 description 10
- 108090000193 Interleukin-1 beta Proteins 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 7
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 7
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 7
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 7
- 150000002611 lead compounds Chemical class 0.000 description 7
- JRHMPHMGOGMNDU-UHFFFAOYSA-N 2-(bromomethyl)-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CBr JRHMPHMGOGMNDU-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000009510 drug design Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000000269 nucleophilic effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 206010013700 Drug hypersensitivity Diseases 0.000 description 4
- 108050001049 Extracellular proteins Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 102000000887 Transcription factor STAT Human genes 0.000 description 4
- 108050007918 Transcription factor STAT Proteins 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 238000001311 chemical methods and process Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000005311 drug allergy Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- OKEGUKCJJVGTKL-UHFFFAOYSA-N 2-acetyloxy-3,5-dibromobenzoic acid Chemical compound CC(=O)OC1=C(Br)C=C(Br)C=C1C(O)=O OKEGUKCJJVGTKL-UHFFFAOYSA-N 0.000 description 2
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108010017312 CCR2 Receptors Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 125000000134 2-(methylsulfanyl)ethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])[*] 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000018213 CC chemokine receptor 2 Human genes 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000010665 Enzyme Interactions Effects 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- AIKKULXCBHRFOS-UHFFFAOYSA-N Formothion Chemical compound COP(=S)(OC)SCC(=O)N(C)C=O AIKKULXCBHRFOS-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- QGVNJRROSLYGKF-UHFFFAOYSA-N thiobarbital Chemical compound CCC1(CC)C(=O)NC(=S)NC1=O QGVNJRROSLYGKF-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6954897P | 1997-12-12 | 1997-12-12 | |
| US60/069,548 | 1997-12-12 | ||
| US10351798P | 1998-10-08 | 1998-10-08 | |
| US60/103,517 | 1998-10-08 | ||
| PCT/US1998/025501 WO1999031265A1 (en) | 1997-12-12 | 1998-12-02 | Compounds and methods for the inhibition of protein-protein interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2312913A1 true CA2312913A1 (en) | 1999-06-24 |
Family
ID=26750190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002312913A Abandoned CA2312913A1 (en) | 1997-12-12 | 1998-12-02 | Compounds and methods for the inhibition of protein-protein interactions |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6465192B2 (https=) |
| EP (1) | EP1038021A4 (https=) |
| JP (1) | JP2002508398A (https=) |
| CA (1) | CA2312913A1 (https=) |
| WO (1) | WO1999031265A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003221884A1 (en) * | 2002-04-10 | 2003-10-27 | Transtech Pharma, Inc. | System and method for data analysis, manipulation, and visualization |
| US7785647B2 (en) * | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
| US20160144642A1 (en) * | 2014-11-24 | 2016-05-26 | Kyocera Document Solutions Inc. | Printing device control method and system with executing command determined from image |
| CN117133371B (zh) * | 2023-10-25 | 2024-01-05 | 烟台国工智能科技有限公司 | 基于人工断键的无模板单步逆合成方法及系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372933A (en) | 1988-10-03 | 1994-12-13 | The Scripps Research Institute | Polypeptides that mimic receptor-induced binding sites, and methods of using same |
| AU7048791A (en) * | 1989-12-01 | 1991-06-26 | Board Of Trustees Of The Leland Stanford Junior University | Promotion of high specificity molecular assembly |
| US5723289A (en) * | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
| DK0580737T3 (da) * | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| FR2675804B1 (fr) * | 1991-04-25 | 1995-04-07 | Propeptide Sa | Procede de synthese de peptides, nouveaux derives d'acides amines mis en óoeuvre dans ce procede et leurs procedes de preparation. |
| FR2679564A1 (fr) * | 1991-07-23 | 1993-01-29 | Inst Nat Sante Rech Med | Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent. |
| US5552534A (en) | 1991-08-22 | 1996-09-03 | The Trustees Of The University Of Pennsylvania | Non-Peptide peptidomimetics |
| US5639603A (en) * | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US5552634A (en) * | 1993-12-14 | 1996-09-03 | Lsi Logic Corporation | Method and apparatus for dissipating heat in an electronic device |
| US5571681A (en) * | 1994-03-10 | 1996-11-05 | The Scripps Research Institute | Chemical event selection by suicide substrate conjugates |
| US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
| US6372933B1 (en) * | 1999-08-26 | 2002-04-16 | Smithkline Beecham Corporation | Process for preparing certain phenyl urea compounds |
-
1998
- 1998-12-02 EP EP98961858A patent/EP1038021A4/en not_active Withdrawn
- 1998-12-02 JP JP2000539163A patent/JP2002508398A/ja not_active Withdrawn
- 1998-12-02 WO PCT/US1998/025501 patent/WO1999031265A1/en not_active Ceased
- 1998-12-02 CA CA002312913A patent/CA2312913A1/en not_active Abandoned
- 1998-12-10 US US09/208,665 patent/US6465192B2/en not_active Expired - Fee Related
-
2002
- 2002-08-15 US US10/219,405 patent/US20030003513A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999031265A1 (en) | 1999-06-24 |
| JP2002508398A (ja) | 2002-03-19 |
| EP1038021A4 (en) | 2005-02-16 |
| US20020031780A1 (en) | 2002-03-14 |
| EP1038021A1 (en) | 2000-09-27 |
| US20030003513A1 (en) | 2003-01-02 |
| US6465192B2 (en) | 2002-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1005361B1 (en) | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY | |
| JP2005509008A (ja) | Ｐｔｐ１ｂの阻害剤およびリガンド | |
| US5721096A (en) | Methods of screening for compounds with ability to alter apolipoprotein AI gene expression | |
| US6465192B2 (en) | Compounds and methods for the inhibition of protein-protein interactions | |
| US20100310540A1 (en) | Methods of screening for compounds that modulate tafia activity, compounds, and methods of using the compounds | |
| JPH1192401A (ja) | ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的 | |
| US7026114B1 (en) | Methods and compositions for monitoring polymer array synthesis | |
| US20050202450A1 (en) | Hypoxia-inducible factor 1alpha variants and methods of use | |
| Gao et al. | Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation | |
| JP2005176846A (ja) | 肥満に関する脂肪組織由来の標的 | |
| JP2006509495A (ja) | 正確なｈｅｒｇ相互作用の測定方法と該相互作用に基づく化合物の改変 | |
| US20030207263A1 (en) | Method of screening therapeutic agents | |
| US20080114079A1 (en) | TRPM2-specfic inhibitors | |
| CN1080762C (zh) | 被检物质的活性测定法 | |
| US7081343B2 (en) | Methods for identifying modulators of NF-KB activity | |
| CN114699405B (zh) | 化合物在制备治疗非酒精性脂肪肝药物中的应用 | |
| EP1137949A1 (en) | Assays for compounds which increase phospholipase a2 activity | |
| US20050158771A1 (en) | Screening assays | |
| CA2332121A1 (en) | Methods for inhibiting tef-3 activity | |
| JP2009039126A (ja) | レクチンに対する高親和性核酸リガンド | |
| WO2000017658A2 (en) | Diagnosis of myocardial disease or stroke using factor ix activation peptide | |
| Ojingwa | Reactivity of acyl glucuronides | |
| Haber | The impact of biotechnology on advances in cardiovascular medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |